Clinical, Immunological, and Molecular Variability of RAG Deficiency: A Retrospective Analysis of 22 RAG Patients
Open Access
- 18 October 2021
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (1) , 130-145
Abstract
Purpose: We described clinical, immunological, and molecular characterization within a cohort of 22 RAG patients focused on the possible correlation between clinical and genetic data. Methods: Immunological and genetic features were investigated by multiparametric flow cytometry and by Sanger or next generation sequencing (NGS) as appropriate. Results: Patients represented a broad spectrum of RAG deficiencies: SCID, OS, LS/AS, and CID. Three novel mutations in RAG1 gene and one in RAG2 were reported. The primary symptom at presentation was infections (81.8%). Infections and autoimmunity occurred together in the majority of cases (63.6%). Fifteen out of 22 (68.2%) patients presented autoimmune or inflammatory manifestations. Five patients experienced severe autoimmune cytopenia refractory to different lines of therapy. Total lymphocytes count was reduced or almost lacking in SCID group and higher in OS patients. B lymphocytes were variably detected in LS/AS and CID groups. Eighteen patients underwent HSCT permitting definitive control of autoimmune/hyperinflammatory manifestations in twelve of them (80%). Conclusion: We reinforce the notion that different clinical phenotype can be found in patients with identical mutations even within the same family. Infections may influence genotype–phenotype correlation and function as trigger for immune dysregulation or autoimmune manifestations. Severe and early autoimmune refractory cytopenia is frequent and could be the first symptom of onset. Prompt recognition of RAG deficiency in patients with early onset of autoimmune/hyperinflammatory manifestations could contribute to the choice of a timely and specific treatment preventing the onset of other complications.Keywords
All Related Versions
Funding Information
- Agenzia Italiana del Farmaco, Ministero della Salute (NET-2011-02350069)
- Childrens’ Hospital Bambino Gesù (RRC-2019-2366867, [RC2020_INFETT_FINOCCHI, RC2020_INFETT_CANCRINI, 202105_INFETT_CANCRINI)
This publication has 47 references indexed in Scilit:
- A novel homozygous mutation in recombination activating gene 2 in 2 relatives with different clinical phenotypes: Omenn syndrome and hyper-IgM syndromeJournal of Allergy and Clinical Immunology, 2012
- Hypomorphic Rag mutations can cause destructive midline granulomatous diseaseBlood, 2010
- Analysis of mutations from SCID and Omenn syndrome patients reveals the central role of the Rag2 PHD domain in regulating V(D)J recombinationJournal of Clinical Investigation, 2010
- Recombinase‐activating gene 1 immunodeficiency: different immunological phenotypes in three siblingsActa Paediatrica, 2009
- RAG-dependent primary immunodeficienciesHuman Mutation, 2006
- A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infectionJournal of Clinical Investigation, 2005
- A variant of SCID with specific immune responses and predominance of T cellsJournal of Clinical Investigation, 2005
- V(D)J Recombination: RAG Proteins, Repair Factors, and RegulationAnnual Review of Biochemistry, 2002
- RAG-1 and RAG-2, Adjacent Genes That Synergistically Activate V(D)J RecombinationScience, 1990
- The V(D)J recombination activating gene, RAG-1Cell, 1989